Clinical Trials Browser

Phase 1/2 × ensartinib × 30 days × Clear all

NCT07448116 2026-03-04

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Phase 1/2 Recruiting

Solid Advanced Tumor